HALO Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 42.95%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 20.73%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 8.86%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Halozyme Therapeutics, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are larger than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 13.23x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.36x versus 8.13x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 17.96%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 20.73%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.81%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Halozyme Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.77% to investors and pays a quarterly dividend of $0.62 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 13.23x while Bristol Myers Squibb Co.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.36x versus 2.20x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 21.47%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Johnson & Johnson's return on equity of 33.27%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 20.73%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics, Inc. is more attractive than Johnson & Johnson.

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 13.23x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.36x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 7.29%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 20.73%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Halozyme Therapeutics, Inc. is more attractive than Phibro Animal Health Corp..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 13.23x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.36x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.